Alacizumab Biosimilar – Anti-KDR, VEGFR2, CD309 mAb – Research Grade

Description of Alacizumab Biosimilar - Anti-KDR, VEGFR2, CD309 mAb - Research Grade

Introduction:

Alacizumab Biosimilar, also known as Anti-KDR, VEGFR2, CD309 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Alacizumab. This biosimilar has been designed to target the same therapeutic targets as the original drug, but at a more affordable cost. In this article, we will discuss the structure, activity, and applications of Alacizumab Biosimilar in detail.

Structure:

Alacizumab Biosimilar is a monoclonal antibody that is composed of two identical heavy chains and two identical light chains. Each chain consists of a variable region and a constant region. The variable region is responsible for binding to the target molecule, while the constant region is responsible for the effector functions of the antibody.

Activity:

The main activity of Alacizumab Biosimilar is to bind to and inhibit the activity of the vascular endothelial growth factor receptor 2 (VEGFR2), also known as CD309. VEGFR2 is a protein that is found on the surface of endothelial cells, which are responsible for forming new blood vessels. When VEGFR2 is activated by its ligand, vascular endothelial growth factor (VEGF), it promotes the growth and proliferation of blood vessels. This process is important for normal physiological functions, such as wound healing and tissue repair. However, in certain diseases, such as cancer, VEGFR2 is overexpressed and contributes to the growth and spread of tumors. By binding to VEGFR2, Alacizumab Biosimilar blocks the binding of VEGF and inhibits the formation of new blood vessels, thereby slowing down the growth and spread of tumors.

Applications:

The main application of Alacizumab Biosimilar is in the treatment of cancer. It has been approved for the treatment of various types of cancer, including colorectal cancer, lung cancer, and breast cancer. In these cancers, VEGFR2 is overexpressed and plays a critical role in tumor growth and progression. By inhibiting VEGFR2, Alacizumab Biosimilar can slow down the growth and spread of tumors, and in some cases, even shrink them.

In addition to cancer, Alacizumab Biosimilar has also shown promising results in the treatment of other diseases where angiogenesis (formation of new blood vessels) plays a role. These include age-related macular degeneration, diabetic retinopathy, and macular edema. In these conditions, abnormal blood vessel growth can lead to vision loss. By inhibiting VEGFR2, Alacizumab Biosimilar can prevent the formation of these abnormal blood vessels and preserve vision.

Research Grade:

Apart from its therapeutic applications, Alacizumab Biosimilar is also available as a research grade antibody. This means that it can be used in laboratory experiments to study the role of VEGFR2 in various diseases and to develop new treatments. The research grade antibody is produced using the same manufacturing process as the therapeutic grade antibody, ensuring high quality and consistency.

Conclusion:

In conclusion, Alacizumab Biosimilar, also known as Anti-KDR, VEGFR2, CD309 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Alacizumab. It binds to and inhibits the activity of VEGFR2, a protein that is overexpressed in various diseases, including cancer. By inhibiting VEGFR2, Alacizumab Biosimilar can slow down the growth and spread of tumors and has been approved for the treatment of various types of cancer. It also has potential applications in other diseases where angiogenesis plays a role. Furthermore, its availability as a research grade antibody makes it a valuable tool for studying VEGFR2 and developing new treatments.

Alacizumab Biosimilar - Anti-KDR, VEGFR2, CD309 mAb binds to Human VEGFR2 Recombinant Protein in indirect ELISA Assay

Immobilized Human VEGFR2 Recombinant Protein (cat. No.PX-P3059) at 0.5µg/mL (100µL/well) can bind to Alacizumab Biosimilar - Anti-KDR, VEGFR2, CD309 mAb (cat. No.PX-TA1167) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450